Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge-Reference-Cited by-同舟云学术

Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge

Published:2020-07-07 Issue:11 Volume:22 Page:1985-1994
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Ford Brian E.¹^ORCID,Chachra Shruti S.¹,Alshawi Ahmed¹,Brennan Alfie²,Harnor Suzannah²^ORCID,Cano Celine²^ORCID,Baker David J.³,Smith David M.⁴,Fairclough Rebecca J.⁴,Agius Loranne¹^ORCID

Affiliation:

1. Biosciences Institute Newcastle University, Medical School Newcastle upon Tyne UK

2. Newcastle Drug Discovery, Newcastle Centre for Cancer, School of Natural and Environmental Sciences Newcastle University Newcastle Upon Tyne UK

3. Bioscience, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Cambridge UK

4. Emerging Innovations Unit Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca Cambridge UK

Funder

Medical Research Council, Canada

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14111

Reference45 articles.

1. Novel glucokinase activators: a patent review (2008 – 2010)

2. A patent review of glucokinase activators and disruptors of the glucokinase – glucokinase regulatory protein interaction: 2011 – 2014

3. GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?

4. Present status of clinical deployment of glucokinase activators

5. Lessons from glucokinase activators: the problem of declining efficacy

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Compromised chronic efficacy of a glucokinase activator AZD1656 in mouse models for common human GCKR variants;Biochemical Pharmacology;2024-11

2. Identification of small molecule glucokinase activators for the treatment of diabetes based on plants from the traditional Chinese medicine: In silico analysis;Microbial Pathogenesis;2024-10

3. Compromised chronic efficacy of a Glucokinase Activator AZD1656 in mouse models for common humanGCKRvariants;2024-07-24

4. Glucokinase activator improves glucose tolerance and induces hepatic lipid accumulation in mice with diet-induced obesity;Liver Research;2023-06

5. The GCKR-P446L gene variant predisposes to raised blood cholesterol and lower blood glucose in the P446L mouse-a model for GCKR rs1260326;Molecular Metabolism;2023-06